Health and Healthcare
Biotechs and Related Hitting 52-Week Lows Too (BBH, AMGN, AMLN, ARNA, GERN, INGN, PGNX, SUPG)
Published:
Last Updated:
Today has been a rough day with more 52-week lows than we can recall in quite some time. The biotechs haven’t been immune. You can even see that the Biotech HOLDRs (BBH) at $160+ are only about 2% above the 52-week lows of $157.95, while the iShares Nasdaq Biotechnology (IBB) ETF at $80.29 is only about half-way in its 52-week trading range of $72.37 to $89.00. The difference is because of the composition.
Here are BIOTECH STOCKS hitting 52-week lows today:
- Amgen (AMGN)
- Amylin Pharma (AMLN)
- Arena Pharma (ARNA)
- Cleveland Biolabs (CBLI)
- Geron (GERN)
- Introgen (INGN)
- Progenics Pharma (PGNX)
- Somaxon Pharma (SOMX)
- Spectrum Pharma (SPPI)
- Supergen (SUPG)
If you wantto see how bad today is look at the master list of 52-week lows we compiled two hours ago with financials, restaurants, retail, REIT, property, tech and more. It’s a huge list.
Jon C. Ogg
January 4, 2008
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
